학술논문
Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting
Document Type
Article
Author
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p7436-7436, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Background: The treatment of acute myeloid leukemia (AML) in older and/or unfit patients consists of a combination of a hypomethylating agent (HMA), such as decitabine and azacitidine, with venetoclax, which can be safely administered in the ambulatory setting. In this study, we aimed to compare the outcomes of the treatment of patients with AML who received chemotherapy with venetoclax and an HMA in an ambulatory setting at an academic center or at a community practice with academic center support.